scholarly journals Occurrence of mental disorders in nonspecific inflammatory bowel diseases: a primary or secondary problem in relation to the biological therapy used?

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Mateusz Olesiak ◽  
Ewa Stelmach
Keyword(s):  
Mental Disorders ◽  
Chronic Diseases ◽  
Steroid Therapy ◽  
Inflammatory Bowel Diseases ◽  
Colitis Ulcerosa ◽  
Common Mental Disorders ◽  
Anxiety And Depression ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Depression Disorders

Abstract Introduction: Nonspecific inflammatory bowel diseases include Crohn’s disease (CD) and ulcerative colitis (CU – colitis ulcerosa), which are chronic diseases characterized by periods of exacerbation and remission. Extraintestinal complications caused by the disease and the applied treatment, mainly steroid therapy, constitute a predisposition to infections and mental disorders such as depressive disorders with apathy, slowness of movement or agitation, and even manic syndromes. Aim and method: The aim of this study was to review the literature on the occurrence of primary and secondary mental disorders in the course of inflammatory bowel diseases. The literature in the Google Scholar database was reviewed using the following keywords: colitis ulcerosa, Crohn disease, depression, mental disorders, inflammatory bowel disease. The time descriptors 2011-2021 were also used. Conclusions: The review of epidemiological studies shows that the most common mental disorders in nonspecific inflammatory bowel diseases are anxiety and depression disorders. The effect of steroid therapy on the development of mental disorders is equally significant. Most of the available empirical data relating to corticosteroids confirm the correlation between the drugs and depressive symptoms, and other psychiatric effects, including mania and psychosis. Summary: As with most chronic diseases, the prevalence of anxiety and depression disorders is higher in nonspecific inflammatory bowel diseases than in the general population.

Prediction of the disease course in inflammatory bowel diseases

2010 ◽  
Vol 151 (8) ◽  
pp. 293-301 ◽  
Author(s):  
Lajos Sándor Kiss ◽  
Péter László Lakatos
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Colitis Ulcerosa ◽  
Disease Course ◽  
Bowel Diseases ◽  
Inflammatory Bowel

A Crohn-betegség (CD) és a colitis ulcerosa (UC) klinikai megjelenése igen változatos lehet a betegség megjelenésekor és a betegség lefolyása során. A legtöbb Crohn-betegnél a betegség lefolyása során különböző szövődmények jelennek meg, szűkület alakulhat ki, illetve perforáció jelentkezhet. A szövődmények miatt a betegek egy része végül sebészi kezelésre szorul. Az utóbbi években éppen ezért a kutatások egyik középpontjába került a betegség progresszióját előrejelző faktorok vizsgálata. Mivel a potenciálisan súlyos lefolyású betegekben a korai immunmodulátor és/vagy biológiai kezelés indokolt, fontos a prediktív faktorok ismerete és minél korábbi meghatározása. Ebben az összefoglaló közleményben a szerzők az irodalomban elérhető azon klinikai, endoszkópiás, laboratóriumi és genetikai faktorokra vonatkozó adatokat szeretnék áttekinteni, amelyek segítséget nyújthatnak a mindennapi gyakorlatban a klinikusok számára a megfelelő kezelési stratégia kiválasztásához.

P009 FINANCIAL VOLATILITY OF INFLAMMATORY BOWEL DISEASES VS OTHER CHRONIC GASTROINTESTINAL DISEASES - USING THE BETA COEFFICIENT TO CATEGORIZE GI DISORDERS

2020 ◽  
Vol 26 (Supplement_1) ◽  
pp. S49-S49
Author(s):  
Lawrence Kosinski ◽  
Siddharth Singh ◽  
Joel Brill ◽  
Sachin Singh ◽  
Leanne Metcalfe ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Chronic Diseases ◽  
Inflammatory Bowel Diseases ◽  
Gastrointestinal Diseases ◽  
Gastrointestinal Disorders ◽  
Relative Volatility ◽  
Bowel Diseases ◽  
Beta Coefficient ◽  
Inflammatory Bowel ◽  
High Beta

Abstract Symptomatic chronic diseases differ in their propensity for serious costly morbidity. Reliable and predictable deterioration presentations can be associated with very narrow margins between symptoms and the onset of serious complications. The inflammatory bowel diseases (IBD): Crohn’s Disease and Ulcerative Colitis are examples of this. As a result, they have high cost per capita with significant variation in that cost. Reliable metrics for assessing the relative volatility of chronic diseases are lacking. In finance, the volatility of a stock is measured using the beta coefficient, a measure of the relative volatility of an individual stock in relation to the that of an index.[i] By definition, the specific index has a beta of 1.0, and individual stocks are ranked according to how much they deviate from the market based on their beta coefficient. A stock that demonstrates more volatility than the market over time has a beta above 1.0. We postulated that chronic gastrointestinal diseases can be profiled using a similar measurement of volatility based on cost. Using a data set of 40,523 members obtained from Health Care Service Corporation, which included professional, facility and pharmacy claims for calendar year 2017, we calculated an index and beta rating for the major gastrointestinal disorders: gastroesophageal reflux disease (GERD), Peptic Ulcer disease (PUD), Gastritis, Celiac disease, Pancreatitis, Irritable Bowel Syndrome (IBS), Crohn’s disease (CD), Ulcerative colitis (UC), Colon Polyps and Diverticulitis: Method: The Total Disease Specific Cost (TDSC) was calculated from claims data for each condition using ICD - Codes.A GI Disease index (GIDI) was created by calculating the TDSC of all of the above conditions. The GIDI TDSC was then segregated into deciles.The cost/decile was then analyzed for each condition and compared against the GI IndexA beta rating (Beta) was calculated using Standard Deviations of the relative cost/decile (SDCD) as follows: Beta = SDCD (Illness)/SDCD (Index) Results: Using this methodology, the GI Index and individual beta ratings are numerically and graphically shown in the figures. Whereas CD and UC have strongly positive Beta scores, the remainder of the GI illnesses do not as compared to the GI Index. Figure 1. Major Gastrointestinal illnesses’ Beta Rating with respect to GI Index Table 1. Summary of major Gastrointestinal illnesses’ cost by decile and Beta Rating Conclusions: Gastrointestinal disorders can be categorized, based on their volatility, into a beta rating[ii]. Disorders associated with high cost and high variability in cost have a high-beta rating compared to the GI disorder index. This is a critical finding as high-beta conditions are those toward which management payments should be focused as they benefit most from patient engagement, care coordination and care managment programs to improve outcomes and control costs. [i] Sharpe W. Portfolio theory and capital markets. New York: McGraw Hill, 1970.[ii] Kosinski L, Brill J; Clinical Gastroenterology and Hepatology Vol. 14, No. 12, P1751-1752

Clinico-pathological profile evaluation in patients affected by chronic inflammatory bowel diseases

2017 ◽  
Vol 41 (S1) ◽  
pp. S320-S320
Author(s):  
F. Travagliati ◽  
E. Borrelli ◽  
S. Martinelli ◽  
L. Dattoli ◽  
D. Ferrarese ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Self Efficacy ◽  
Social Impact ◽  
Anxiety And Depression ◽  
Control Group ◽  
Psychological Wellness ◽  
Bowel Diseases ◽  
Chron's Disease ◽  
Inflammatory Bowel ◽  
Competing Interest

IntroductionInflammatory bowel diseases (IBDs) have high social impact. Aetiology is still unknown, however multifactorial genesis is surely implicated. We tried to correlate IBDs and psychological distress through evaluated psychometrical instruments and subsequently to relate subjective influences with gastroenteric clinical manifestation, defining new critical elements on which IBD are based.MethodsIn our study, we included 57 participants, selected according to their diagnosis, between those attending our gastrointestinal ambulatory: 26 had Chron's disease, while 31 had ulcerative colitis. 78 people without gastroenteric or psychiatric disorder were also included in the study as control group. Psychometric questionnaires were administered to evaluate anxiety and depressive symptoms, quality of live, self-efficacy and resilience (Fig. 1).ResultsLevels of anxiety and depression were higher in patients with IBDs than in the control group. STAI-Y highlighted higher state anxiety and trait anxiety levels in first group. HADS showed higher scores in ill patients, as well as CD-RISC showed a more impaired resilience. EQ-VAS, PGWBI and GSE revealed significant differences in health status, psychological wellness and self-efficacy between the two groups.ConclusionsIBDs seem related to psychological diseases. Affected patients have higher anxiety and depression levels than general population as well as lower self-efficacy and resilience. Those elements being strictly linked to physical discomfort contributes to develop a loop in which patients get caught. Creating a model of integrated cooperation between gastroenterologist and psychiatrist during treatment of patients with IBDs seems fundamental to grant at once all the professional figures each patient needs for better care.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals Διερεύνηση του πιθανού διαμεσολαβητικού ρόλου των πρωτεϊνών θερμικού shock ανάμεσα στο ψυχοφυσιολογικό στρες και τις οργανικές παθήσεις

2013 ◽  
Author(s):  
Ηλίας Βλάχος
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Depression Scale ◽  
Anxiety And Depression ◽  
Depression And Anxiety ◽  
Hospital Anxiety ◽  
Cytoprotective Effect ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Anxiety Levels

Objective – To investigate the hypothesis that depression and anxiety levelscould beassociatedwith theinduction of theantiapoptoticHeatShock Protein70 (HSP70) inthe colon of patients with Inflammatory Bowel Diseases (IBD),namelyulcerativecolitis(UC)andCrohn‟sdisease(CD).Methods- 54 consecutive, hospitalized IBD patients in relapse gave theirinformed consent, filled out psychometric questionnaires [Zung DepressionRatingScale(ZDRS),SpielbergerState-TraitAnxietyInventory(STAIFormXI,IIas a state andas a trait), Hospital Anxiety and Depression Scale (HADS)].Simultaneously, intestinal biopsies were taken to be diagnosed in a blindedmanner by two pathologists. The type and severity of inflammation wereassessedoneachsection withhematoxylin/eosinstaining.Thelocalizationandintensity of expression ofHSP70 expression were studiedimmunohistochemically.Results:31/54patientssufferedfromactiveUC,14fromCDand9wereinremission.InducibleHSP70(HSP70i)wasscarcelydetectableintheintestinalmucosa of UC and CD patients. There was statistically significant correlationbetween depression and anxiety levels and inducible HSP70 in thepolymorphonuclearcells(PMN)ofpatientswithactiveUC.Conclusion: Inducible HSP70 is clearly expressed in PMN cells of IBD patientsand in patients with active UC this finding positively correlates with thedepression and anxiety levels. Given the antiapoptotic, cytoprotective effect ofHSP70onPMNcells and thedestructiverole thatPMNcellsexertonintestinalmucosa of IBD patients, light could be shed on the psychosomatic aspect ofautoimmunityinthesediseases.

scholarly journals Possible role of selected IGR and SLC22A4/SLC22A5 loci in development of inflammatory bowel diseases

2009 ◽  
Vol 150 (29) ◽  
pp. 1375-1380 ◽  
Author(s):  
Lilla Lakner ◽  
Veronika Csöngei ◽  
Lili Magyari ◽  
Márta Varga ◽  
Pál Miheller ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Colitis Ulcerosa ◽  
Pcr Rflp ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Az idiopathiás krónikus gyulladásos bélbetegség kialakulásában környezeti tényezők, immunológiai és genetikai faktorok egyaránt szerepet játszanak. Az utóbbi években a CARD15 gén mellett egyre több adat támasztja alá más gének, többek között az 5q31-33 régióban elhelyezkedő IBD5 locus (MIM#606348) szerepét. Egyes tanulmányok ezen régióban az SLC22A4 gén C1672T szubsztitúciójának, illetve az SLC22A5 gén G-207C transzverziójának együttes szerepét hangsúlyozzák, különösen Crohn-betegség kialakulásában, míg más szerzők új minor hajlamosító tényezőket azonosítottak az IBD5 kromoszómarégióban, ezek az IGR-variánsok. Célkitűzés: Az SLC22A4 C1672T és SLC22A5 G-207C mutációk mellett az IGR2096a_1 (rs12521868) és az IGR2198a_1 (rs11739135) polimorfizmusok szerepének vizsgálata gyulladásos bélbetegség kialakulásában. Betegek és módszer: Vizsgálatunk során 440 gyulladásos bélbeteg (206 Crohn- és 234 colitis ulcerosás beteg), valamint 279 kontrollegyén perifériás vérmintájából PCR-RFLP technikával végeztünk DNS-analízist. Eredmények: Sem a C1672T, sem a G-207C allélek, sem a TC haplotípus nem bizonyult rizikófaktornak sem Crohn-betegség, sem colitis ulcerosa esetében. Ezzel ellentétben mindkét minor IGR allél frekvenciája: mind az IGR2096a_1 T (48,1%), mind az IGR2198a_1 C (46,1%) szignifikánsan magasabb volt Crohn-betegségben a kontrollokéhoz (38,5%, 38,4%) képest (p<0,05). Korra és nemre standardizált regressziós analízissel mindkét allélnél fokozott rizikót észleltünk Crohn-betegség vonatkozásában (T-allél: OR=1,694, 95%-os CI: 1,137–2,522, p=0,010, C-allél: OR=1,644, 95%-os CI=1,103–2,449, p=0,015). Colitis ulcerosa esetén nem találtunk összefüggést a két IGR-variáns és a betegség kialakulása között. Következtetés: az IGR minor alléleknek a környező kaukázusi népcsoportoktól eltérően magyarországi populációban szerepük lehet a Crohn-betegség kialakulásában.

Sign in / Sign up

Export Citation Format

Share Document